Heterogeneous lower urinary tract symptoms often limit the clinical capacity to differentiate among underlying lower urinary tract dysfunctions, as distinct conditions frequently present with overlapping clinical manifestations that traditionally necessitate invasive testing. In an expert review published in Nature Reviews Urology, researchers evaluated the diagnostic, therapeutic, and prognostic utility of objective urinary biomarkers as non-invasive adjuncts to standard urological evaluation. Because different dysfunctions present with similar clinical complaints, invasive examinations such as videourodynamic study and cystoscopy have conventionally been required to establish definitive phenotyping and prevent inappropriate escalation of medical therapy or unnecessary surgical interventions.
The underlying pathophysiology of lower urinary tract dysfunction encompasses several overlapping biological axes, including chronic inflammation, urothelial dysfunction, sensory hyperinnervation, oxidative stress, and structural tissue and neurogenic remodelling. These cellular and tissue-level processes are directly reflected in alterations of urinary protein signatures, making urine an accessible matrix for molecular interrogation. By tracking these distinct molecular disturbances, urinary proteins provide measurable biological indicators that mirror local bladder and lower urinary tract alterations.
Specific objective urinary biomarkers, spanning inflammatory proteins, neurogenic proteins, and oxidative stress indicators, show measurable increases across diverse pathological entities. These conditions encompass neurogenic voiding dysfunction, overactive bladder, bladder outlet obstruction, dysfunctional voiding, detrusor underactivity, and interstitial cystitis or bladder pain syndrome. Although single individual biomarkers rarely achieve sufficient diagnostic accuracy to distinguish complex conditions on their own, composite multimarker panels and clustering approaches effectively address biological heterogeneity to support clinically actionable patient subtyping.
Integrating urinary biomarker clusters with validated clinical symptom measures, diagnostic imaging, and baseline physiological parameters substantially refines diagnostic precision. Modern analytical methodologies, including decision trees, nomograms, and unsupervised clustering algorithms, allow clinicians to map complex molecular profiles into structured diagnostic pathways. For instance, decision-tree models constructed from urinary biomarkers have been developed to aid in distinguishing specific female lower urinary tract dysfunctions presenting with nearly identical clinical presentations.
Beyond diagnostic phenotyping, biomarker-informed categorization provides a rational framework to guide treatment selection and anticipate therapeutic responses. Emerging bladder therapies that specifically target chronic inflammation, provide antioxidant and regenerative effects, or enhance local microvascular blood supply can be more effectively tailored to patients harboring matching biomarker phenotypes. Correlating elevated biomarker subtypes directly with pathological mechanisms allows clinicians to move beyond empirical symptom management toward targeted, individualized interventions.
Ultimately, incorporating non-invasive biomarker panels alongside standard clinical variables provides practical nomograms and predictive models in functional urology. By linking quantifiable inflammatory, neurogenic, and oxidative protein patterns to underlying pathology, these multidimensional tools aim to optimize therapeutic strategies, improve outcome forecasting, and mitigate the reliance on invasive diagnostic procedures in adult lower urinary tract dysfunction.
Subject of Research: Urinary biomarkers and non-invasive phenotyping for adult lower urinary tract dysfunction
Article Title: Urinary biomarkers for diagnosis, treatment selection and prognostication in adult lower urinary tract dysfunction
Article References: Jiang, Y.-H., Jhang, J.-F., Yu, W.-R., & Kuo, H.-C. (2026). Urinary biomarkers for diagnosis, treatment selection and prognostication in adult lower urinary tract dysfunction. Nature Reviews Urology. https://doi.org/10.1038/s41585-026-01202-2
Image Credits: AI Generated
DOI: 10.1038/s41585-026-01202-2
Keywords: lower urinary tract dysfunction, urinary biomarkers, urology, interstitial cystitis, bladder pain syndrome, bladder outlet obstruction, overactive bladder, detrusor underactivity, detrusor overactivity, dysfunctional voiding, neurogenic voiding dysfunction, chronic inflammation, urothelial dysfunction, oxidative stress, sensory hyperinnervation, videourodynamics, nomograms
News Source: Ophelia Keating. (November 12, 2026). Urinary Biomarker Profiles Offer Non-Invasive Approach for Phenotyping Lower Urinary Tract Dysfunction. Scienmag.



